By George Ongkojoyo 
In a landmark development for the field of oncology, a multidisciplinary team of researchers in Germany has achieved a feat long considered a "holy grail" of cancer biology: the successful cultivation of stable tumor organoids directly from the blood samples of breast cancer patients. This breakthrough, spearheaded by the German Cancer Research Center (DKFZ), the Heidelberg Stem Cell Institute (HI-STEM), and the National Center for Tumor Diseases (NCT) Heidelberg, provides a transformative platform for studying the "germ cells" of metastasis in real-time. By growing these "mini-tumors" in a laboratory setting, scientists have successfully identified the molecular signaling pathways that allow cancer cells to survive aggressive treatments, paving the way for highly personalized, resistance-proof therapies.
The Silent Threat: Understanding Metastatic Breast Cancer
Breast cancer remains one of the most prevalent malignancies worldwide. While early-stage diagnosis and surgical intervention have significantly boosted survival rates over the last thirty years, metastatic breast cancer remains a formidable and often terminal challenge. Metastasis occurs when cancer cells detach from the primary tumor and migrate through the bloodstream or lymphatic system to colonize vital organs, such as the lungs, liver, bone, or brain. These secondary growths are notoriously difficult to treat because they often harbor genetic mutations that differ from the original tumor, making them inherently resistant to standard chemotherapy and hormonal treatments.
The primary drivers of this spread are Circulating Tumor Cells (CTCs). These cells act as the "seeds" or "germ cells" of the disease. However, studying CTCs has historically been an exercise in extreme difficulty. In a typical patient, CTCs are vanishingly rare, often numbering fewer than ten cells per several billion healthy blood cells. Their scarcity and fragility meant that, until now, they could not be reliably propagated in a culture dish. This limitation forced researchers to rely on snapshots of the disease or complex animal models, leaving a massive gap in our understanding of how these cells evolve to survive systemic therapy.
A Decisive Breakthrough in Laboratory Cultivation
The research team, led by Professor Andreas Trumpp, Head of the Division of Stem Cells and Cancer at the DKFZ and Director of HI-STEM, has bypassed decades of technical hurdles by establishing a protocol to grow these rare cells into three-dimensional organoids. Unlike traditional two-dimensional cell cultures, organoids are complex, 3D structures that mimic the architecture and biological behavior of the actual tumor within the human body.
Previously, the only way to multiply CTCs for study was through "xenografting"—a process where human cancer cells are injected into immunodeficient mice. This method is not only time-consuming and expensive but often takes months to produce results, a timeline that is often too slow to influence clinical decisions for patients with advanced disease. By successfully cultivating these organoids directly from blood samples in a laboratory dish, the Heidelberg team has shortened the window for analysis and created a renewable source of patient-specific tumor material.
This achievement is particularly significant because it allows for "longitudinal" study. Because blood samples are minimally invasive—unlike surgical biopsies of internal organs—researchers can take multiple samples over the course of a patient’s treatment. This allows them to observe, in real-time, how the tumor organoids change in response to different drugs, offering a window into the evolution of therapy resistance.
The Molecular Architecture of Resistance: NRG1 and HER3
With the ability to grow and study these organoids, the researchers turned their attention to the "why" of therapy resistance. Through the clinical registry trial known as CATCH (Characterization of Adjuvant Treatment in Chronic HER2-positive Breast Cancer) at the NCT Heidelberg, the team analyzed the genetic and molecular profiles of the cultivated CTCs.
They discovered a specific signaling pathway that acts as a survival engine for the cancer cells. Central to this process is a protein called NRG1 (Neuregulin 1). The researchers found that NRG1 acts as a potent biological "fuel" for the circulating tumor cells. It binds to a receptor on the cell surface known as HER3. Once bound, HER3 pairs with another well-known receptor, HER2, to trigger a cascade of internal signals that prevent the cell from dying and encourage rapid proliferation.
This discovery clarifies why many breast cancer treatments eventually fail. Even when doctors use targeted drugs to block HER2—a common strategy in many breast cancer cases—the presence of NRG1 and its interaction with HER3 can provide enough survival signaling to keep the cancer cells alive.
The "Bypass" Mechanism: A New Challenge for Oncology
Perhaps the most significant finding of the study, published by first author Roberto Würth and colleagues, is the identification of a cellular "fail-safe" or bypass mechanism. The researchers observed that even when the NRG1-HER2/3 pathway was successfully inhibited by medication, the tumor cells did not necessarily perish. Instead, they adapted by activating an alternative signaling pathway controlled by the Fibroblast Growth Factor Receptor 1 (FGFR1).
"With the help of such ‘bypasses’, tumors react to external influences, for example to targeted therapies against HER2," explains Roberto Würth. This molecular plasticity is what makes metastatic breast cancer so resilient. When one door is closed by a drug, the cell simply opens another to ensure its survival.
However, the organoid model allowed the team to test a solution to this problem. By applying a "double blockade"—simultaneously targeting both the NRG1-HER2/3 pathway and the FGFR1 pathway—they were able to effectively shut down the survival signals. In laboratory experiments, this combined approach not only stopped the growth of the tumor organoids but successfully induced programmed cell death (apoptosis) in the resistant cells.
The CATCH Trial and the Shift Toward Liquid Biopsies
The success of this research is deeply rooted in the collaborative infrastructure of the CATCH trial. This clinical registry is dedicated to analyzing the genetic diversity of breast cancer cells in patients whose disease has progressed despite treatment. By integrating laboratory breakthroughs with clinical data, the researchers are moving closer to the era of the "liquid biopsy."
In traditional oncology, a biopsy involves the surgical removal of tissue. This is often painful, carries risks, and may not be feasible if the metastasis is located in a dangerous area of the brain or liver. Furthermore, a single biopsy only provides a snapshot of the tumor at one location. Because metastatic cancer is "heterogeneous"—meaning different metastases in the same patient can have different genetic mutations—a single tissue biopsy may not tell the whole story.
The ability to grow organoids from a simple blood draw (liquid biopsy) solves these problems. It provides a systemic view of the cancer cells circulating in the body and allows for repeated testing as the disease evolves. This methodology represents a paradigm shift in how oncologists might monitor treatment efficacy and adjust prescriptions in real-time.
Analysis: Implications for Personalized Medicine
The implications of the Heidelberg team’s work are profound. By using a patient’s own CTC-derived organoids, doctors could potentially conduct "preclinical trials" in a dish before administering a drug to the patient. This would allow clinicians to identify which drug combinations are most effective for a specific individual’s unique cancer profile, sparing patients from the side effects of treatments that are unlikely to work.
Furthermore, this research opens the door to preventing metastasis before it starts. If CTCs can be identified and their specific survival pathways mapped early in the disease, targeted therapies could be deployed to eliminate these "germ cells" while they are still in the bloodstream, effectively neutralizing the threat before they can take root in other organs.
Andreas Trumpp emphasizes the transformative nature of this breakthrough: "The possibility of cultivating CTCs from the blood of breast cancer patients as tumor organoids in the laboratory at different time points is a decisive breakthrough. This makes it much easier to investigate how tumor cells become resistant to therapies. On this basis, we can develop new treatments that may also specifically kill resistant tumor cells."
Chronology of the Research and Future Directions
The journey to this discovery has been years in the making:
- 2008: Establishment of HI-STEM as a partnership between DKFZ and the Dietmar Hopp Foundation, focusing on cancer stem cells.
- Early 2010s: Andreas Trumpp’s laboratory identifies that only a tiny sub-fraction of CTCs are actually capable of initiating metastases.
- Mid-2010s: The CATCH trial begins at NCT Heidelberg, creating a massive repository of clinical data and patient samples.
- 2020-2023: Researchers refine the 3D cultivation techniques, successfully moving from mouse models to direct in-vitro (culture dish) growth of CTC organoids.
- 2024: Publication of the findings regarding the NRG1-HER3 and FGFR1 pathways and the successful application of the double blockade.
While the results are a major scientific victory, the team remains cautious. The method must now undergo rigorous clinical trials to ensure that the drug responses observed in the organoids accurately predict how a human patient will respond. There are also logistical hurdles to clear, such as scaling the cultivation process and reducing costs to make the technology accessible to the wider population.
However, the foundation has been laid. The ability to grow a patient’s cancer in a dish, watch it evolve, and find its "Achilles’ heel" marks a new chapter in the fight against breast cancer. By tackling the disease at its root—the circulating "germ cells"—science is moving closer to a future where metastatic cancer is no longer a terminal diagnosis, but a manageable, and perhaps even preventable, condition.